Nectero Medical Revenue and Competitors
Estimated Revenue & Valuation
- Nectero Medical's estimated annual revenue is currently $2.9M per year.
- Nectero Medical's estimated revenue per employee is $125,500
- Nectero Medical's total funding is $19.5M.
Employee Data
- Nectero Medical has 23 Employees.
- Nectero Medical grew their employee count by 28% last year.
Nectero Medical's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | VP, CMC | Reveal Email/Phone |
4 | VP – Development and Program Management | Reveal Email/Phone |
5 | VP – Clinical Affairs | Reveal Email/Phone |
6 | VP, Marketing | Reveal Email/Phone |
7 | VP Regulatory Affairs | Reveal Email/Phone |
8 | VP Operations Nectero Medical | Reveal Email/Phone |
9 | VP Quality | Reveal Email/Phone |
10 | Director Clinical Operations | Reveal Email/Phone |
Nectero Medical Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $13.8M | 55 | 49% | N/A | N/A |
#2 | $9.8M | 39 | 0% | N/A | N/A |
#3 | $0.5M | 4 | 0% | N/A | N/A |
#4 | $20.3M | 81 | 65% | N/A | N/A |
#5 | $10.8M | 43 | 0% | N/A | N/A |
#6 | $28.1M | 112 | -3% | $83.2M | N/A |
#7 | $6.5M | 26 | 0% | N/A | N/A |
#8 | $8M | 19 | 0% | N/A | N/A |
#9 | $11M | 57 | 6% | N/A | N/A |
#10 | $12M | 48 | 7% | N/A | N/A |
What Is Nectero Medical?
Nectero Medical is developing a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms (AAA). The Nectero EAST®, or Endovascular Aneurysm Stabilization Treatment System, delivers a compound with a proprietary molecule known as a Stabilizer Agent to the site of the aneurysm. The Stabilizing Agent: * Inhibits further breakdown of the aneurysm by disrupting the “aortic degradation process”. * Strengthens the vessel wall by cross-linking within the tissue; this wall strengthening lowers the risk of rupture. Our technology allows for earlier intervention in a much safer manner; this can prevent or significantly delay the need for major endovascular (EVAR) or surgical repair. By preventing further degradation of the aneurysm and strengthening the aortic tissue around the aneurysm, many patients can live out their normal life span and never need to face the challenges of EVAR or Surgical repair.
keywords:N/A$19.5M
Total Funding
23
Number of Employees
$2.9M
Revenue (est)
28%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.7M | 23 | -28% | N/A |
#2 | $3.2M | 23 | -15% | N/A |
#3 | $2.3M | 23 | 0% | N/A |
#4 | $85.2M | 23 | 10% | $5.5M |
#5 | $1.8M | 23 | 10% | $9.3M |